89bio

U.S. biotechnology company 89bio (NASDAQ: ETNB) has secured the services of China-based Contract Development and Manufacturing Organization (CDMO) BiBio Biopharma Engineering to construct an API facility in China. The facility will supply the active pharmaceutical ingredient (API) for 89bio’s lead pipeline candidate, pegozafermin, an investigational FGF21 analog currently in Phase…